Table 2.

Effect of lycopene (1-5 μM) on cell cycle progression in different human cancer cell lines after 96 hours

Cell Lines	Cell Cycle phase	CT	1 μM	3 μM	5 μM
HT-29	G0/G1	77.14 ± 0.02	84.37 ±0.10*	40.29 ± 5.40**	46.07 ± 0.68**
	S	8.31 ± 0.45	4.40 ± 1.06	19.59 ± 4.02*	9.30 ± 0.47
	G2/M	13.41 ± 0.70	10.17 ± 0.32*	34.72 ± 0.86**	40.03 ± 0.38**
T84	G0/G1	28.14 ± 0.01	41.84 ± 1.53**	32.97 ± 0.28**	36.06 ± 0.06**
	S	17.86 ± 1.03	17.52 ± 0.05	18.85 ± 0.20	19.39 ± 3.93
	G2/M	43.67 ± 0.01	38.51 ± 1.48*	45.64 ± 0.51	50.23 ± 0.01*
MCF-7	G0/G1	17.10 ± 1.56	22.45 ± 0.78*	19.30 ± 0.99*	20.20 ± 1.13*
	S	26.25 ± 0.35	26.95 ± 0.07	24.15 ± 1.20	22.95 ± 1.48
	G2/M	40.50 ± 0.71	33.85 ± 1.20*	30.20 ± 0.28*	24.95 ± 0.07**
A549	G0/G1	65.82 ± 2.62	63.48 ± 4.47	66.62 ± 3.59	61.54 ± 1.14
	S	14.10 ± 3.29	13.61 ± 2.64	11.55 ± 2.67	14.90 ± 0.36
	G2/M	21.31 ± 0.83	24.56 ± 2.21*	23.40 ± 1.41*	25.18 ± 0.73*
DU145	G0/G1	56.24 ± 7.90	46.12 ±15.97	25.99 ± 7.43**	16.76 ± 1.61**
	S	12.19 ± 3.79	16.36 ± 3.25	8.02 ± 2.14	8.57 ± 1.70
	G2/M	29.89 ± 3.99	31.26 ± 5.85	56.97 ± 6.24**	55.93 ± 5.53**
HepG2	G0/G1	59.68 ± 0.09	47.17 ± 4.18*	23.23 ± 0.59**	19.91 ± 5.82**
	S	12.33 ± 0.86	10.68 ± 2.74	7.04 ± 0.52*	7.91 ± 2.71
	G2/M	26.39 ± 0.41	36.63 ± 7.25*	57.84 ± 1.53**	59.49 ±7.52**
Hela	G0/G1	62.42 ± 0.01	62.48 ± 0.08	63.49 ± 1.33	63.59 ± 2.26
	S	10.35 ± 0.18	9.02 ± 0.59	8.19 ± 0.24	7.86 ± 0.33
	G2/M	25.87 ± 0.27	26.36 ± 0.28	24.90 ± 0.32	26.19 ± 0.12
Hep-2	G0/G1	62.78 ± 4.35	69.50 ± 4.65	63.39 ± 0.07	61.83 ± 7.97
	S	18.73 ± 2.57	12.72 ± 3.64	16.79 ± 0.73	17.77 ± 5.70
	G2/M	20.66 ± 1.48	18.65 ± 1.92	20.31 ± 0.72	20.53 ± 2.57

Results are expressed as the percentage of total cells. Data represent mean ± SD values of triplicate experiments. Tukey–Kramer Multiple Comparison test; *p < 0.05; **p < 0.01